Leerink Partnrs Downgrades Hologic (NASDAQ:HOLX) to Hold

Hologic (NASDAQ:HOLX) was downgraded by equities research analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for Hologic’s Q3 2025 earnings at $1.10 EPS, FY2025 earnings at $4.27 EPS, Q1 2026 earnings at $1.14 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.17 EPS, FY2026 earnings at $4.60 EPS and FY2027 earnings at $4.88 EPS.

A number of other equities analysts have also commented on HOLX. William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday. Evercore ISI dropped their price objective on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday. Raymond James reissued an “outperform” rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a report on Thursday. Stephens restated an “overweight” rating and set a $84.00 target price on shares of Hologic in a report on Thursday. Finally, Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $85.77.

Hologic Stock Down 1.3 %

Shares of NASDAQ:HOLX opened at $64.58 on Thursday. The company has a 50 day moving average of $72.33 and a 200-day moving average of $77.76. Hologic has a one year low of $63.88 and a one year high of $84.67. The stock has a market cap of $14.58 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 2.35 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. On average, sell-side analysts forecast that Hologic will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.88% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after buying an additional 2,174,093 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after buying an additional 544,889 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Hologic during the fourth quarter valued at $27,007,000. Swedbank AB lifted its position in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after acquiring an additional 306,562 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after buying an additional 238,222 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.